Paradigm Biopharmaceuticals has announced the completion of enrolment in its pivotal Phase 3 trial of Zilosul injectable pentosan polysulfate sodium for knee osteoarthritis, a milestone that moves the company into the next phase of clinical and corporate catalysts. …
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Season 5, Episode 22
July 3, 2026 - - Podcast -
Is that a subtle but meaningful shift conceding the potential need for a response to global realities?
July 3, 2026 - -
New once weekly therapy offers extended protection for people with haemophilia A
July 3, 2026 - - Latest News -
Nothing else grows below this self-serving and broken institutional framework
July 3, 2026 - - Latest News -
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Medicines Australia chief says next negotiation is about getting comfortable with being uncomfortable
July 3, 2026 - - Latest News -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News